There is limited information on HBV-antiviral therapy among HIV/HBV co-infected pregnant women.
Phase II randomized controlled trial of a regimen containing tenofovir (TDF) /lamivudine (3TC), versus 3TC, in HIV/HBV co-infected pregnant women in China. The HBV virological response was compared in study arms (Clinical Trials registration: #NCT01125696).
Median decline of HBV DNA was 2.60 log10 copies/ml in the TDF-3TC arm; 2.24 log10 copies/ml in the 3TC arm (p=0.41). All women achieved delivery HBV DNA levels <6 log10 copies/ml. CONCLUSIONS
Initiation of either regimen led to achieving HBV DNA levels below the threshold associated with perinatal HBV transmission.